Stay updated with breaking news from Biontech Ribomab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well as first half 2022 revenues of €9.6 billion, net profit of €5.4 billion
First quarter revenues of €6.4 billion1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to
Investegate announcements from BioNTech SE, BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Fourth quarter and full year revenues of €5.5 billion1 and €19.0 billion1, respectivelyFull year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.872)Expect to authorize